alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Exhibit 13.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Tsakos Energy Navigation Limited (the Company) on Form 20-F for
the period ending December 31, 2008 as filed with the Securities and Exchange Commission on the date hereof (the Report), I, Nikolas P. Tsakos, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C.
§ 1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that, based on my knowledge:



| | (1) | The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
| | --- | ---------------------------------------------------------------------------------------------------------------------



| | (2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
| | --- | ----------------------------------------------------------------------------------------------------------------------------------------------------



/s/ Nikolas P. TsakosNikolas P. TsakosPresident and Chief Executive OfficerDate: April 30, 2009
#### WELCH MOTOR CAR CO. OF NEW YORK, Appellant, v. P. BRADY & SON CO., Respondent, et al.

(Supreme Court, Appellate Division, First Department.

March 22, 1912.)

Action by the Welch Motor Car Company of New York against the P. Brady & Son Company, impleaded with others. N. W. Kern-good, for appellant. J. T. Smith, for respondent. No opinion. Judgment and order affirmed, with costs. Order filed.
exhibit_10-2.htm










Exhibit 10.2


 





 


March 5, 2015


 


Partner Communications Company Ltd.


8 Amal Street


Afeq Industrial Park


Rosh-Ha’ayin  48103


Israel


 


Dear Sirs:







On behalf of Giza Singer Even, 7 Jabotinsky St. Ramat-Gan (the “Consultant”), I hereby confirm that the Consultant has reviewed the information set forth in the Annual Report on Form 20-F for the year ended December 31, 2014 (the “Form 20-F”), for Partner Communications Company Ltd. under Item 5A.1d “Acquisition of 012 Smile”, Item 5A.1q “Critical Accounting Estimates and Judgments”, and in Note 4 and Note 12 to the consolidated financial statements included in the Form 20-F, with respect to testing for impairment of assets and the results thereof.







The Consultant hereby confirms the information referred to above and consents to being named in the Form 20-F as an “expert”.








By:____/s/_______


 




Giza Singer Even LTD.







Name: Alex Shechter


Title: Partner
#### Gustavo B. SAMPAIO, Plaintiff-Appellant, v. CLIENT SERVICES, INC., Defendant-Appellee.

No. 08-11954

Non-Argument Calendar.

United States Court of Appeals, Eleventh Circuit.

Jan. 7, 2009.

Donald A. Yarbrough, Fort Lauderdale, FL, for Plaintiff-Appellant.

Dale T. Golden, Golden *&*Scaz, PLLC, Tampa, FL, for Defendant-Appellee.

Before ANDERSON, MARCUS and PRYOR, Circuit Judges.

PER CURIAM:

Appellant makes two arguments on appeal. First, appellant argues that the District Court’s dismissal of his ease might be considered an acceptance by appellant of appellee’s offer of judgment. Appellant objects to that because the offer apparently purported to include a release of unknown parties. With respect to the first argument, we do not constrúe the district court’s dismissal of the case as encompassing any order that appellee’s offer of judgment was deemed accepted. Rather, we construe the district court’s judgment as acknowledging that appellee had agreed to pay appellant $1,001 plus appellant’s reasonable attorney’s fees and costs up to the date of the offer of judgment, that same was the maximum recovery to which appellant was entitled, and that there was no longer a live case or controversy. In other words, appellant’s concern in its first argument is resolved, because appellant is not deemed to have accepted appellee’s offer of judgment.

Appellant’s second argument challenges the validity of the offer of judgment because it was faxed rather than mailed. We doubt the argument has merit, but in any event, the issue is moot. Appellant is entitled to be paid $1,001 plus reasonable attorney’s fees and costs up to the date of the offer — the maximum to which appellant could have been entitled — and details *497with respect to the offer of judgment are not material.

The judgment of the district court is affirmed.1

AFFIRMED.

1

. Neither party shall be entitled to recover from the other any attorney’s fees on this appeal, and each party shall bear its own costs.
**Exhibit 32(i)**

CERTIFICATION SECTION 1350

Inconnection with the Quarterly Report of Penns Woods Bancorp, Inc. (the “Company”)on Form 10-Q for the period ending September 30, 2006, as filed with theSecurities and Exchange Commission on the date hereof (the “Report”), I, RonaldA. Walko, Chief Executive Officer, certify, pursuant to 18 U.S.C. Section 1350,as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)           theReport fully complies with the requirements of Section 13(a) or 15(d) of theSecurities Exchange Act of 1934; and

(2)           the informationcontained in the Report fairly presents, in all material respects, thefinancial condition and result of operations of the Company.
| /s/ Ronald A. Walko     |   |
|-------------------------|--------|
| Ronald A. Walko         |
| Chief Executive Officer |
|                    |
| November 7, 2006        |

 

----
IN THE UNITED STATES DISTRICT COURT

FOR THE NORTHERN DISTRICT OF INDIANA

HAMMOND DIVISION

UNITED STATES OF AMERICA, )

)

Plaintiff, )

)

v. ) No. 2:14-CR-101

)

JOHN HENRY RAY, )

)

Defendant. )

ORDER

This matter is before the Court on the Findings and

Recommendation of the Magistrate Judge Upon a Plea of Guilty by

Defendant John Henry Ray (DE #26) filed on December 16, 2015. No

objections have been filed to the Magistrate Judge’s findings and

recommendations upon a plea of guilty. Accordingly, the Court now

ADOPTS those findings and recommendations, ACCEPTS the guilty plea

of Defendant John Henry Ray, and FINDS the Defendant guilty of

Count 1 of the Indictment. 

Sentencing in this matter will be set by the Court by separate

order. 

DATED: January 12, 2016 /s/ RUDY LOZANO, Judge

United States District Court
MI CHAEL FRANCI S MURR AY, Plaintiff, v. HARL EY G. L

APPI N, Def endant. UNI TED STATES DI STRI CT COURT

FOR THE DI STRI CT OF COLUMBIA
Civil Action No. 09-00992 DAR

F INAL JUDG MENT I n acc ordanc e with the Memora ndum Opinion and Orde r filed on this date, judg ment is here by enter ed in favor of De fenda nt with respec t to all of Plainti ff’ s claims.

_____/s/______________ DEB ORAH A. ROB I

NSON United States Mag istrate Judge
[Federal Register Volume 86, Number 125 (Friday, July 2, 2021)]
[Notices]
[Page 35307]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-14191]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2020-N-0026]


Issuance of Priority Review Voucher; Rare Pediatric Disease 
Product

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is announcing the 
issuance of a priority review voucher to the sponsor of a rare 
pediatric disease product application. The Federal Food, Drug, and 
Cosmetic Act (FD&C Act) authorizes FDA to award priority review 
vouchers to sponsors of approved rare pediatric disease product 
applications that meet certain criteria. FDA is required to publish 
notice of the award of the priority review voucher. FDA has determined 
that RYPLAZIM (plasminogen, human-tvmh), manufactured by Prometic 
Bioproduction, Inc., meets the criteria for a priority review voucher.

FOR FURTHER INFORMATION CONTACT: Myrna Hanna, Center for Biologics 
Evaluation and Research, Food and Drug Administration, 10903 New 
Hampshire Ave., Bldg. 71, Rm. 7301, Silver Spring, MD 20993-0002, 240-
402-7911.

SUPPLEMENTARY INFORMATION: FDA is announcing the issuance of a priority 
review voucher to the sponsor of an approved rare pediatric disease 
product application. Under section 529 of the FD&C Act (21 U.S.C. 
360ff), FDA will award priority review vouchers to sponsors of approved 
rare pediatric disease product applications that meet certain criteria. 
FDA has determined that RYPLAZIM (plasminogen, human-tvmh), 
manufactured by Prometic Bioproduction, Inc., meets the criteria for a 
priority review voucher. RYPLAZIM (plasminogen, human-tvmh) is 
indicated for the treatment of patients with plasminogen deficiency 
type 1 (hypoplasminogenemia).
    For further information about the Rare Pediatric Disease Priority 
Review Voucher Program and for a link to the full text of section 529 
of the FD&C Act, go to https://www.fda.gov/industry/developing-products-rare-diseases-conditions/rare-pediatric-disease-rpd-designation-and-voucher-programs. For further information about 
RYPLAZIM (plasminogen, human-tvmh), go to the Center for Biologics 
Evaluation and Research Cellular and Gene Therapy Products website at 
https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/approved-cellular-and-gene-therapy-products.

    Dated: June 25, 2021.
Lauren K. Roth,
Acting Principal Associate Commissioner for Policy.
[FR Doc. 2021-14191 Filed 7-1-21; 8:45 am]
BILLING CODE 4164-01-P
U.S. flagAn official website of the United States government
                    Here's how you know **Official websites use .gov**
                            
                            A **.gov** website belongs to an official government organization in the United States.
 **Secure .gov websites use HTTPS**
                            
                            A **lock** (                            
                              A locked padlock                                                      
                            
                            ) or **https://** means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.


Menu Agricultural Research Service
						
                    U.S. DEPARTMENT OF AGRICULTURE
 Northeast Area
 close



    Research

                    Research Projects
                                    Publications
                                    Collaborations
                                    News
                People

                    Staff Listing
                                    Careers


        
                Northeast Area Cities

                    Washington, D.C.
                            Newark, Delaware
                            Boston, Massachusetts
                            Beltsville, Maryland (BHNRC)
                            Beltsville, Maryland (BARC)
                            Frederick, Maryland
                            Orono, Maine
                            Geneva, New York
                            Ithaca, New York
                            University Park, Pennsylvania
                            Wyndmoor, Pennsylvania
                            Kearneysville, West Virginia
                            Leetown, West Virginia
                            Burlington, Vermont


                    Civil Rights & EEO Policy StatementsSearch small
                    Search
            
            ARS Home
                                About ARS
                                Contact Us




ARS Home Northeast Area Docs





- Visitor Information
- Friends of Agricultural Research
- Student Discovery Garden
- Environmental Accomplishments at BARC
- BARC Field Day
- Climate Change
- Food Safety/Security
- Nutrition
- Bioenergy
- Sustainable Farming
- Genomics

images for navheadline bar


Return to top


Connect with ARS Sign up


ARS Home
                            USDA.gov
                            Plain Writing
                            Policies & Links
                            Civil Rights Statements
                            FOIA
                            Accessibility Statement
                            Privacy Policy
                            Non-Discrimination Statement
                            Quality of Information
                            USA.gov
                            WhiteHouse.gov
<TABLE> <S> <C>

<ARTICLE>                     5
       
<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                              Dec-31-1998
<PERIOD-END>                                   Jun-30-1998
<CASH>                                                 256
<SECURITIES>                                             0
<RECEIVABLES>                                      165<F1>
<ALLOWANCES>                                         1<F1>
<INVENTORY>                                            747
<CURRENT-ASSETS>                                     1,223
<PP&E>                                             136<F2>
<DEPRECIATION>                                     120<F2>
<TOTAL-ASSETS>                                       1,529
<CURRENT-LIABILITIES>                                  927
<BONDS>                                                268
<PREFERRED-MANDATORY>                                    0
<PREFERRED>                                              0
<COMMON>                                                 1
<OTHER-SE>                                             109
<TOTAL-LIABILITY-AND-EQUITY>                         1,529
<SALES>                                              1,060
<TOTAL-REVENUES>                                     1,072
<CGS>                                                  835
<TOTAL-COSTS>                                          900
<OTHER-EXPENSES>                                         0
<LOSS-PROVISION>                                         0
<INTEREST-EXPENSE>                                       8
<INCOME-PRETAX>                                        152
<INCOME-TAX>                                            56
<INCOME-CONTINUING>                                     96
<DISCONTINUED>                                           0
<EXTRAORDINARY>                                          0
<CHANGES>                                                0
<NET-INCOME>                                            96
<EPS-PRIMARY>                                         1.31
<EPS-DILUTED>                                         1.27

<FN>
Amounts inapplicable or not disclosed as a separate line on the Statement
of Financial Position or Results of Operations are reported as 0 herein.
<F1> Notes and accounts receivable - trade are reported net of allowances for
     doubtful accounts in the Consolidated Balance Sheet.

<F2> Property, plant and equipment are reported net of accumulated
     depreciation in the Consolidated Balance Sheet.
</FN>
        

</TABLE>
<PAGE>


                                  EXHIBIT 32.2

                        CERTIFICATION OF PERIODIC REPORT


I, Barry J. Susson, Chief Financial Officer of Deb Shops, Inc. (the "Company"),
certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C.
Section 1350, that:

     (1) the Quarterly Report on Form 10-Q of the Company for the quarterly
period ended April 30, 2005 (the "Report") fully complies with the requirements
of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m
or 78o(d)); and

     (2) the information contained in the Report fairly presents, in all
material respects, the financial condition and results of operations of the
Company.



Date: June 9, 2005






                                                     Barry J. Susson, CPA
                                                     --------------------
                                                     Barry J. Susson, CPA
                                                     Chief Financial Officer
```

[Congressional Bills 112th Congress]
[From the U.S. Government Publishing Office]
[S. 55 Introduced in Senate (IS)]

112th CONGRESS
  1st Session
                                 S. 55

 To amend title XIX of the Social Security Act to provide for coverage 
  of services provided by nursing school clinics under State Medicaid 
                               programs.

_______________________________________________________________________

                   IN THE SENATE OF THE UNITED STATES

             January 25 (legislative day, January 5), 2011

  Mr. Inouye introduced the following bill; which was read twice and 
                  referred to the Committee on Finance

_______________________________________________________________________

                                 A BILL

 
 To amend title XIX of the Social Security Act to provide for coverage 
  of services provided by nursing school clinics under State Medicaid 
                               programs.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Nursing School Clinics Act of 
2011''.

SEC. 2. MEDICAID COVERAGE OF SERVICES PROVIDED BY NURSING SCHOOL 
              CLINICS.

    (a) In General.--Section 1905(a) of the Social Security Act (42 
U.S.C. 1396d(a)) is amended--
            (1) in paragraph (28), by striking ``and'' at the end;
            (2) by redesignating paragraph (29) as paragraph (30); and
            (3) by inserting after paragraph (28), the following new 
        paragraph:
            ``(29) nursing school clinic services (as defined in 
        subsection (ee)) furnished by or under the supervision of a 
        nurse practitioner or a clinical nurse specialist (as defined 
        in section 1861(aa)(5)), whether or not the nurse practitioner 
        or clinical nurse specialist is under the supervision of, or 
        associated with, a physician or other health care provider; 
        and''.
    (b) Nursing School Clinic Services Defined.--Section 1905 of the 
Social Security Act (42 U.S.C. 1396d) is amended by adding at the end 
the following new subsection:
    ``(ee) The term `nursing school clinic services' means services 
provided by a health care facility operated by an accredited school of 
nursing which provides primary care, long-term care, mental health 
counseling, home health counseling, home health care, or other health 
care services which are within the scope of practice of a registered 
nurse.''.
    (c) Conforming Amendment.--Section 1902(a)(10)(C)(iv) of the Social 
Security Act (42 U.S.C. 1396a(a)(10)(C)(iv)) is amended by inserting 
``and (29)'' after ``(24)''.
    (d) Effective Date.--The amendments made by this section shall be 
effective with respect to payments made under a State plan under title 
XIX of the Social Security Act (42 U.S.C. 1396 et seq.) for calendar 
quarters commencing with the first calendar quarter beginning after the 
date of enactment of this Act.
                                 <all>
```
Exhibit 32.2

                      Statement of Chief Financial Officer
         Pursuant to Section 1350 of Title 18 of the United States Code


Pursuant to Section 1350 of Title 18 of the United States Code, the undersigned,
Henry P. Herms, the Vice President - Finance and Chief Financial Officer of
CopyTele, Inc., hereby certifies that:

1.       The Company's Form 10-Q Quarterly Report for the period ended January
         31, 2004 (the "Report") fully complies with the requirements of Section
         13(a) or 15(d) of the Securities Exchange Act of 1934; and

2.       The information contained in the Report fairly presents, in all
         material respects, the financial condition and results of operations of
         the Company.


                                            /s/ Henry P. Herms
                                            ---------------------------
                                            Henry P. Herms
                                            Vice President - Finance and
February 26, 2004                           Chief Financial Officer
I 

109TH CONGRESS 

1ST SESSION H. R. 2160 

To extend the duty suspension on 2-Phenylbenzimidazole-5-sulfonic acid. 

IN THE HOUSE OF REPRESENTATIVES 

MAY 5, 2005 

Mr. BROWN of South Carolina introduced the following bill; which was 

referred to the Committee on Ways and Means 

A BILL 

To extend the duty suspension on 2-Phenylbenzimidazole5-sulfonic acid. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. 2-PHENYLBENZIMIDAZOLE-5-SULFONIC ACID. 

4 (a) IN GENERAL.—Heading 9902.01.35 of the Har5 monized Tariff Schedule of the United States (relating to 

6 2-Phenylbenzimidazole-5-sulfonic acid) is amended by 

7 striking ‘‘12/31/2006’’ and inserting ‘‘12/31/2008’’. 

8 (b) EFFECTIVE DATE.—The amendment made by 

9 subsection (a) applies to goods entered, or withdrawn from 
2 

•HR 2160 IH 

1 warehouse for consumption, on or after the 15th day after 

2 the date of the enactment of this Act. 

Æ